论文部分内容阅读
目的:通过对卵巢疾病患者血清CA125、CA153、CA199和CEA进行联合检测提高卵巢癌早期诊断率。方法:本研究对44例卵巢癌患者,30例卵巢良性疾病患者,100例健康对照者血清,利用罗氏2010全自动电化学发光仪进行CA125、CA153、CA199和CEA联合检测。结果:结果显示恶性组血清CA125、CA153、CA199和CEA水平及阳性率显著高于良性疾病组和正常对照组,P﹤0.05,阳性率分别为68.2%、65.9%、52.2%和36.4%。联合检测CA125、CA153、CA199和CEA的阳性率,卵巢癌为93%,卵巢良性疾病为30%,均显著高于健康对照者,且显著高于检测单一肿瘤标志物的阳性率。结论:联合检测CA125、CA153、CA199和CEA对于卵巢癌和卵巢良性肿瘤的诊断和鉴别诊断具有重要价值。
OBJECTIVE: To improve the early diagnosis rate of ovarian cancer through the combined detection of serum CA125, CA153, CA199 and CEA in patients with ovarian disease. Methods: In this study, 44 patients with ovarian cancer, 30 patients with benign ovarian disease, 100 healthy controls serum, using Roche 2010 automatic electrochemical luminescence CA125, CA153, CA199 and CEA joint detection. Results: The results showed that the positive rates of serum CA125, CA153, CA199 and CEA in malignant group were significantly higher than those in benign disease group and normal control group (P <0.05). The positive rates were 68.2%, 65.9%, 52.2% and 36.4% respectively. The positive rate of combined detection of CA125, CA153, CA199 and CEA was 93% in ovarian cancer and 30% in benign ovarian disease, which were significantly higher than those in healthy controls and significantly higher than the positive rate of detecting single tumor markers. Conclusion: The combined detection of CA125, CA153, CA199 and CEA is of great value in the diagnosis and differential diagnosis of ovarian and benign ovarian tumors.